Free Trial

StockNews.com Upgrades Aemetis (NASDAQ:AMTX) to "Sell"

Aemetis logo with Oils/Energy background

Aemetis (NASDAQ:AMTX - Get Free Report) was upgraded by StockNews.com to a "sell" rating in a research note issued on Wednesday.

Several other research analysts have also weighed in on AMTX. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Aemetis in a report on Monday. Ascendiant Capital Markets decreased their price target on shares of Aemetis from $20.00 to $19.00 and set a "buy" rating for the company in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Aemetis presently has an average rating of "Moderate Buy" and a consensus target price of $12.95.

Read Our Latest Report on Aemetis

Aemetis Stock Performance

Shares of AMTX stock traded up $0.04 during trading hours on Wednesday, reaching $2.63. The company had a trading volume of 363,140 shares, compared to its average volume of 793,738. The company has a market capitalization of $130.80 million, a P/E ratio of -1.16 and a beta of 1.35. Aemetis has a twelve month low of $2.10 and a twelve month high of $7.03. The stock's fifty day simple moving average is $3.29 and its 200 day simple moving average is $2.99.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million during the quarter, compared to analysts' expectations of $77.79 million. During the same quarter last year, the company posted ($0.59) earnings per share. As a group, equities analysts expect that Aemetis will post -2.02 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in shares of Aemetis in the second quarter worth about $306,000. Rhumbline Advisers grew its position in Aemetis by 2,837.1% during the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company's stock worth $157,000 after purchasing an additional 50,528 shares in the last quarter. Hutchinson Capital Management CA acquired a new stake in Aemetis during the 2nd quarter valued at $70,000. Susquehanna Fundamental Investments LLC raised its stake in Aemetis by 287.4% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company's stock valued at $379,000 after purchasing an additional 93,536 shares during the period. Finally, FMR LLC lifted its holdings in shares of Aemetis by 68.2% in the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company's stock valued at $52,000 after purchasing an additional 9,137 shares in the last quarter. 27.02% of the stock is owned by institutional investors and hedge funds.

About Aemetis

(Get Free Report)

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.

See Also

Analyst Recommendations for Aemetis (NASDAQ:AMTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Buy this Stock before Trump Takes Office! (From Behind the Markets) (Ad)

Should you invest $1,000 in Aemetis right now?

Before you consider Aemetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.

While Aemetis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines